Haas G P, Hillman G G, Redman B G, Pontes J E
Department of Urology, Wayne State University School of Medicine, Detroit, Michigan.
CA Cancer J Clin. 1993 May-Jun;43(3):177-87. doi: 10.3322/canjclin.43.3.177.
Immunologic approaches to the therapy of metastatic renal cell carcinoma have provided moderate improvement in response rates for a disease that is extremely resistant to all forms of treatment. This article reviews recent clinical efforts using immunotherapy for renal cell carcinoma, including the adoptive transfer of cytotoxic killer cells and/or the use of biologic response modifiers, such as interferon and interleukin-2.
对于对所有形式治疗都极具抗性的转移性肾细胞癌，免疫治疗方法已使缓解率有了一定程度的提高。本文综述了近期使用免疫疗法治疗肾细胞癌的临床研究，包括细胞毒性杀伤细胞的过继性转移和/或使用生物反应调节剂，如干扰素和白细胞介素-2。
